Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Treating COVID-19 With Hydroxychloroquine (TEACH): A Multicenter, Double-Blind Randomized Controlled Trial in Hospitalized Patients
Robert J. Ulrich, Andrea B. Troxel, Ellie Carmody, et al.
Open Forum Infectious Diseases (2020) Vol. 7, Iss. 10
Open Access | Times Cited: 69

Showing 1-25 of 69 citing articles:

Drug treatments for covid-19: living systematic review and network meta-analysis
Reed Siemieniuk, Jessica Bartoszko, Dena Zeraatkar, et al.
BMJ (2020), pp. m2980-m2980
Open Access | Times Cited: 796
Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials
Cathrine Axfors, Andreas M. Schmitt, Perrine Janiaud, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 272
How COVID-19 has fundamentally changed clinical research in global health
Jay Park, Robin Mogg, Gerald E. Smith, et al.
The Lancet Global Health (2021) Vol. 9, Iss. 5, pp. e711-e720
Open Access | Times Cited: 175
ESCMID COVID-19 living guidelines: drug treatment and clinical management
Michele Bartoletti, Özlem Kurt Azap, Aleksandra Barać, et al.
Clinical Microbiology and Infection (2021) Vol. 28, Iss. 2, pp. 222-238
Open Access | Times Cited: 139
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (September 2022)
Adarsh Bhimraj, Rebecca L. Morgan, Amy Hirsch Shumaker, et al.
Clinical Infectious Diseases (2022) Vol. 78, Iss. 7, pp. e250-e349
Open Access | Times Cited: 120
An overview on the treatments and prevention against COVID-19
Yunes Panahi, Armita Mahdavi Gorabi, Sona Talaei, et al.
Virology Journal (2023) Vol. 20, Iss. 1
Open Access | Times Cited: 48
Adverse effects of remdesivir, hydroxychloroquine and lopinavir/ritonavir when used for COVID-19: systematic review and meta-analysis of randomised trials
Ariel Izcovich, Reed Siemieniuk, Jessica Bartoszko, et al.
BMJ Open (2022) Vol. 12, Iss. 3, pp. e048502-e048502
Open Access | Times Cited: 46
Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19: an international collaborative meta-analysis of randomized trials
Cathrine Axfors, Andreas M. Schmitt, Perrine Janiaud, et al.
medRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 56
Adjunctive Nutraceutical Therapies for COVID-19
Lalita Subedi, Stephanie Tchen, Bhakta Prasad Gaire, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 4, pp. 1963-1963
Open Access | Times Cited: 45
Efficacy and safety of hydroxychloroquine as pre-and post-exposure prophylaxis and treatment of COVID-19: A systematic review and meta-analysis of blinded, placebo-controlled, randomized clinical trials.
Paulo Ricardo Martins‐Filho, Lis Campos Ferreira, Luana Heimfarth, et al.
The Lancet Regional Health - Americas (2021) Vol. 2, pp. 100062-100062
Open Access | Times Cited: 45
Interventions for treatment of COVID-19: Second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)
Sophie Juul, Emil Eik Nielsen, Joshua Feinberg, et al.
PLoS ONE (2021) Vol. 16, Iss. 3, pp. e0248132-e0248132
Open Access | Times Cited: 44
Use of pragmatic and explanatory trial designs in acute care research: lessons from COVID-19
Jonathan D. Casey, Laura M. Beskow, Jeremy Brown, et al.
The Lancet Respiratory Medicine (2022) Vol. 10, Iss. 7, pp. 700-714
Open Access | Times Cited: 35
Drug repositioning in the COVID-19 pandemic: fundamentals, synthetic routes, and overview of clinical studies
Elisa Souza Vaz, Sandra V. Vassiliades, Jeanine Giarolla, et al.
European Journal of Clinical Pharmacology (2023) Vol. 79, Iss. 6, pp. 723-751
Open Access | Times Cited: 16
Immunomodulatory therapies for SARS-CoV-2 infection: a systematic literature review to inform EULAR points to consider
Alessia Alunno, Aurélie Najm, Xavier Mariette, et al.
Annals of the Rheumatic Diseases (2021) Vol. 80, Iss. 6, pp. 803-815
Open Access | Times Cited: 38
Efficacy of COVID-19 Treatments: A Bayesian Network Meta-Analysis of Randomized Controlled Trials
Chenyang Zhang, Huaqing Jin, Yi Feng Wen, et al.
Frontiers in Public Health (2021) Vol. 9
Open Access | Times Cited: 38
Clinical Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP)
Matteo Bassetti, Daniele Roberto Giacobbe, Paolo Bruzzi, et al.
Infectious Diseases and Therapy (2021) Vol. 10, Iss. 4, pp. 1837-1885
Open Access | Times Cited: 33
Antivirals and the Potential Benefits of Orally Inhaled Drug Administration in COVID-19 Treatment
Gokben Sahin, Özlem Akbal Dağıstan, Meltem Culha, et al.
Journal of Pharmaceutical Sciences (2022) Vol. 111, Iss. 10, pp. 2652-2661
Open Access | Times Cited: 25
Exploring trial publication and research waste in COVID-19 randomised trials of hydroxychloroquine, corticosteroids, and vitamin D: a meta-epidemiological cohort study
Lisa Fincham, Ameer Hohlfeld, Mike Clarke, et al.
BMC Medical Research Methodology (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 3
Revised Korean Society of Infectious Diseases/National Evidence-based Healthcarea Collaborating Agency Guidelines on the Treatment of Patients with COVID-19
Sun Bean Kim, Seungeun Ryoo, Kyungmin Huh, et al.
Infection and Chemotherapy (2021) Vol. 53, Iss. 1, pp. 166-166
Open Access | Times Cited: 26
The impact of therapeutics on mortality in hospitalised patients with COVID-19: systematic review and meta-analyses informing the European Respiratory Society living guideline
Megan Crichton, Pieter Goeminne, Krizia Tuand, et al.
European Respiratory Review (2021) Vol. 30, Iss. 162, pp. 210171-210171
Open Access | Times Cited: 24
Efficacy of Chloroquine and Hydroxychloroquine for the Treatment of Hospitalized COVID-19 Patients: A Meta-Analysis
Jiawen Deng, Fangwen Zhou, Kiyan Heybati, et al.
Future Virology (2021) Vol. 17, Iss. 2, pp. 95-118
Open Access | Times Cited: 24
Efficacy and safety of current medications for treating severe and non-severe COVID-19 patients: an updated network meta-analysis of randomized placebo-controlled trials
Qinglin Cheng, Chen Jun-fang, Qingjun Jia, et al.
Aging (2021) Vol. 13, Iss. 18, pp. 21866-21902
Open Access | Times Cited: 22
Care for adults with COVID ‐19: living guidelines from the National COVID ‐19 Clinical Evidence Taskforce
Heath White, Steve McDonald, Bridget E. Barber, et al.
The Medical Journal of Australia (2022) Vol. 217, Iss. 7, pp. 368-378
Open Access | Times Cited: 14
Identification of Suitable Drug Combinations for Treating COVID-19 Using a Novel Machine Learning Approach: The RAIN Method
Aliakbar Kiaei, Nader Salari, Mahnaz Boush, et al.
Life (2022) Vol. 12, Iss. 9, pp. 1456-1456
Open Access | Times Cited: 12
Outcomes after early treatment with hydroxychloroquine and azithromycin: An analysis of a database of 30,423 COVID-19 patients
P. Brouqui, Matthieu Million, Philippe Parola, et al.
New Microbes and New Infections (2023) Vol. 55, pp. 101188-101188
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top